Healthcare · Biotechnology
Price
$9.28
Market Cap
$119.0M
Employees
66
Beta
1.25
Avg Volume
359,075
CEO
Juli Blanche
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Runs with full report
Price Overview
Last updated: Jul 8, 2026 7:17pm (just now)
Current data · timestamped when a report runs
$9.28
Change · Jul 8
+0.03 (+0.32%)
Day Range
$8.88 – $9.34
52-Week Range
$3.53 – $9.62
50-Day MA
$7.18
200-Day MA
$5.80
Volume
1,031,629.00
Analyst Price Targets
Low
$19.00
Consensus
$19.50
High
$20.00
(4 analysts)
Share Structure
Outstanding
12,828,154.00
Float
9,845,225.00
Free Float
76.7%
Normal free float
— 76.7% of shares trade freely, ~23.3% held by insiders/institutions
Healthy float typical of established companies. Good liquidity for entering and exiting positions without major price impact.
Small absolute float (9.8M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.61
Stock Price: $9.28
EPS (Diluted): -3.56
EPS (Diluted): -3.56
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.58
Stock Price: $9.28
Total Equity: $92.25M
Shares: 12,826,078
Total Equity: $92.25M
Shares: 12,826,078
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.19
Market Cap: $119.05M
Total Debt: $22.40M
Cash: $110.82M
EBITDA: -$42.43M
Total Debt: $22.40M
Cash: $110.82M
EBITDA: -$42.43M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
-$28.7M
Market Cap: $119.05M
Total Debt: $22.40M
Cash: $110.82M
Total Debt: $22.40M
Cash: $110.82M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
1.56
Stock Price: $9.28
Revenue: $34.26M
Shares: 12,826,078
Revenue: $34.26M
Shares: 12,826,078
EV/Sales (Total value vs revenue — works when P/E can't)
API-0.84
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
100.0%
Gross Profit: $34.26M
Revenue: $34.26M
Revenue: $34.26M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-152.2%
Operating Income: -$52.15M
Revenue: $34.26M
Revenue: $34.26M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-133.4%
Net Income: -$45.72M
Revenue: $34.26M
Revenue: $34.26M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-79.6%
Net Income: -$45.72M
Total Equity: $92.25M
Total Equity: $92.25M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-28.4%
Operating Income: -$52.15M
Tax Rate: 0.0%
Equity: $92.25M
Total Debt: $22.40M
Cash: $110.82M
Tax Rate: 0.0%
Equity: $92.25M
Total Debt: $22.40M
Cash: $110.82M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
13.32
Current Assets: $118.74M
Current Liabilities: $8.91M
Current Liabilities: $8.91M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.24
Short-Term Debt: $0.00
Long-Term Debt: $22.40M
Total Debt: $22.40M
Total Equity: $92.25M
Long-Term Debt: $22.40M
Total Debt: $22.40M
Total Equity: $92.25M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$2.67
Revenue: $34.26M
Shares: 12,826,078
Shares: 12,826,078
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$7.19
Total Equity: $92.25M
Shares: 12,826,078
Shares: 12,826,078
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-5.14
Operating CF: -$65.84M
CapEx: -$85,000
Shares: 12,826,078
CapEx: -$85,000
Shares: 12,826,078
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $9.28
Stock Price: $9.28
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$45.72M
Net Income: -$45.72M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares DTIL against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $115.5M | $25.1M | $48.7M | $68.7M | $34.3M |
| Operating Expenses | $154.9M | $87.4M | $92.5M | $94.9M | $86.4M |
| Operating Income | -$39.4M | -$62.3M | -$43.7M | -$26.2M | -$52.1M |
| Net Income | -$30.6M | -$111.6M | -$61.3M | $7.2M | -$45.7M |
| EBITDA | -$20.3M | -$62.8M | -$32.0M | $13.5M | -$42.4M |
| EPS | $-15.60 | $-38.10 | $-15.96 | $1.05 | $-3.56 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $143.7M | $189.6M | $116.7M | $85.9M | $110.8M |
| Total Current Assets | $161.8M | $199.1M | $136.4M | $95.0M | $118.7M |
| Total Assets | $211.5M | $238.2M | $159.8M | $136.4M | $154.4M |
| Current Liabilities | $36.0M | $59.7M | $50.0M | $15.0M | $8.9M |
| Long-Term Debt | $2.5M | $22.2M | $0 | $22.3M | $22.4M |
| Total Liabilities | $120.3M | $177.7M | $140.9M | $80.0M | $62.2M |
| Total Equity | $91.2M | $60.4M | $18.9M | $56.4M | $92.2M |
| Retained Earnings | -$316.7M | -$428.3M | -$489.6M | -$482.5M | -$528.2M |
Cash Flow (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$10.9M | -$45.8M | -$84.1M | -$58.4M | -$65.8M |
| Capital Expenditure | -$5.8M | -$3.3M | -$2.3M | $-250,000 | $-85,000 |
| Free Cash Flow | -$16.7M | -$49.1M | -$86.4M | -$58.7M | -$65.9M |
| Acquisitions (net) | $0 | $0 | $8.0M | $60,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $53.9M | $45.9M | -$72.9M | -$8.2M | $28.7M |
Analyst Estimates (Annual)
Last updated: Jul 8, 2026 7:17pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$14.4M $9.0M – $19.8M
|
$18.5M $10.2M – $29.3M
|
$25.4M $14.0M – $40.4M
|
$120.6M $66.5M – $191.5M
|
| EBITDA |
-$7.6M -$10.5M – -$4.7M
|
-$9.7M -$15.5M – -$5.4M
|
-$13.4M -$21.3M – -$7.4M
|
-$63.6M -$101.0M – -$35.0M
|
| Net Income |
-$29.5M -$34.9M – -$24.1M
|
-$28.2M -$37.9M – -$18.5M
|
-$27.1M -$47.9M – -$11.3M
|
-$7.9M -$14.0M – -$3.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -78.3% | +94.1% | +41.0% | -50.1% |
| Gross Profit Growth | -78.3% | +94.1% | +41.0% | -50.1% |
| Operating Income Growth | -58.2% | +29.8% | +40.2% | -99.3% |
| Net Income Growth | -264.8% | +45.1% | +111.7% | -738.0% |
| EBITDA Growth | -209.7% | +49.0% | +142.2% | -413.7% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-03 | Brown Melinda | A-Award | 20,979.00 | $0.00 | $0 |
| 2026-06-03 | Frankel Stanley | A-Award | 20,979.00 | $0.00 | $0 |
| 2026-06-03 | Germano Geno J | A-Award | 20,979.00 | $0.00 | $0 |
| 2026-06-03 | Pire Shari Lisa | A-Award | 20,979.00 | $0.00 | $0 |
| 2026-06-03 | Buehler Kevin | A-Award | 20,979.00 | $0.00 | $0 |
| 2026-05-20 | Buehler Kevin | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Buehler Kevin | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Frankel Stanley | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Frankel Stanley | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Brown Melinda | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Brown Melinda | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Pire Shari Lisa | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Pire Shari Lisa | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Germano Geno J | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-05-20 | Germano Geno J | M-Exempt | 21,000.00 | $0.00 | $0 |
| 2026-02-17 | Amoroso Michael | M-Exempt | 67,797.00 | $0.00 | $0 |
| 2026-02-18 | Amoroso Michael | S-Sale | 20,559.00 | $3.84 | $78,947 |
| 2026-02-17 | Amoroso Michael | M-Exempt | 67,797.00 | $0.00 | $0 |
| 2026-02-17 | Kelly John Alexander | M-Exempt | 27,584.00 | $0.00 | $0 |
| 2026-02-18 | Kelly John Alexander | S-Sale | 8,149.00 | $3.84 | $31,292 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for DTIL — it's generated by the pipeline (
market-narrative step).
No community reviews yet for DTIL.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.392 · 5bda1781 · 2026-07-08 16:12:24